Fig. 2From: Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)A Progression-free survival and B overall survival by CR. CI confidence interval, CR complete response, NE not evaluable, OS overall survival, PFS progression-free survivalBack to article page